First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
17.79
+0.89 (5.27%)
May 18, 2026, 4:00 PM EDT - Market closed
TRAX Market Cap
TRAX has a market cap or net worth of $620.74 million as of May 19, 2026.
Market Cap
620.74M
Enterprise Value
334.28M
1-Year Change
n/a
Ranking
Category
Stock Price
$17.79
Market Cap Chart
Since April 6, 2026, TRAX's market cap has decreased from $660.23M to $620.74M, a decrease of -5.98%. That is a compound annual growth rate of -41.49%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 18, 2026 | 620.74M | 5.27% |
| May 15, 2026 | 589.68M | -6.94% |
| May 14, 2026 | 633.65M | -1.06% |
| May 13, 2026 | 640.42M | 3.48% |
| May 12, 2026 | 618.88M | -5.06% |
| May 11, 2026 | 651.89M | -3.99% |
| May 8, 2026 | 678.99M | 9.65% |
| May 7, 2026 | 619.22M | -12.00% |
| May 6, 2026 | 703.66M | -4.44% |
| May 5, 2026 | 736.33M | 3.11% |
| May 4, 2026 | 714.09M | -8.18% |
| May 1, 2026 | 777.68M | -3.82% |
| Apr 30, 2026 | 808.61M | -1.57% |
| Apr 29, 2026 | 821.46M | 17.91% |
| Apr 28, 2026 | 696.71M | 10.77% |
| Apr 27, 2026 | 628.95M | -0.33% |
| Apr 24, 2026 | 631.04M | -4.42% |
| Apr 23, 2026 | 660.23M | 0.69% |
| Apr 22, 2026 | 655.71M | 11.00% |
| Apr 21, 2026 | 590.73M | -8.60% |
| Apr 20, 2026 | 646.33M | -17.37% |
| Apr 17, 2026 | 782.20M | -11.38% |
| Apr 16, 2026 | 882.62M | 3.46% |
| Apr 14, 2026 | 853.08M | 3.37% |
| Apr 13, 2026 | 825.28M | 1.06% |
| Apr 10, 2026 | 816.60M | 2.17% |
| Apr 9, 2026 | 799.22M | -4.96% |
| Apr 8, 2026 | 840.92M | 27.37% |
| Apr 7, 2026 | 660.23M | - |
| Apr 6, 2026 | 660.23M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Candel Therapeutics | 642.58M |
| Aclaris Therapeutics | 631.28M |
| Gyre Therapeutics | 598.49M |
| CorMedix | 592.31M |
| Forte Biosciences | 586.10M |
| Arvinas | 585.85M |
| Kyverna Therapeutics | 574.43M |
| Altimmune | 554.25M |